Table 1.

Ongoing trial evaluating the impact of omission/reduction of RT for BC patients.

Trial Name	Main Inclusion Criteria	Profiling Risk	Study Design	Ref.
PRECISION trial (NCT02653755)	50–75 years old Conserving-surgery for pT1 N0 ER+ (≥10%) or PR+, HER2- and G1/2	PAM50 transcriptional profile used for risk stratification.	Non randomized phase II trial	[33]
NCT03646955	Age ≥ 60 years Conserving-surgery for pT1 N0 ER ≥10% HER2- non-lobular G1/2	Clinical risk stratification	Randomized phase III trial	[34]
NCT05371860	Age ≥ 40 years HER2 positive early BC cT1-3, N0, M0 before NACT and targeted HER2 therapy Documented pCR after NACT	Clinical risk stratification	Non randomized trial	[35]
DESCARTES trial (NCT05416164)	Age ≥ 18 years ER positive/HER2 negative, HER2+ (ER/PR +/−) or TNBC cT1-2, N0, M0 before NACT Documented pCR after NACT	Clinical risk stratification	Non randomized trial	[36]
NCT04517266	Age ≥ 18 years high risk BC (≥2 clinical risk factors) p T > 1, N1 Radical or conserving surgery and ALND	Clinical risk stratification to omit the irradiation of internal mammary nodes	Randomized trial	[37]

Abbreviations: ER: estrogen receptor, PR: progesterone receptor, HER2: epidermal growth receptor 2; G1/2: grade 1 or 2; PAM50: prediction analyses of microarray 50; NACT: neo-adjuvant chemotherapy, pCR: pathological complete response; TNBC: triple negative breast cancer; ALND: axillary lymph node dissection.